Heart Failure in Kidney Transplant Recipients: Narrative Review of Risk Factors, Therapy, and Current Gaps in Management [0.03%]
肾移植受者的充血性心力衰竭：风险因素、治疗及目前管理缺陷的叙述性回顾
Anukul Ghimire,Gaeth Al-Zaneen,Jacob B Michaud et al.
Anukul Ghimire et al.
Among kidney transplant recipients (KTR), cardiovascular disease remains the leading cause of mortality, with heart failure (HF) being especially common in this population. Risk factors for HF in KTR can be categorized as traditional (risks...
In-Hospital and 1-Year Outcomes of Octogenarian and Nonagenarian Patients with Severely Calcified Coronary Lesions Treated with Rotational Atherectomy [0.03%]
冠状动脉严重钙化病变患者行旋磨治疗的院内及1年期临床结果：八旬和九旬老年患者的预后分析
Mohamed Samy,Ahmad Alali,Oleg Schiopu et al.
Mohamed Samy et al.
Introduction: Severely calcified coronary lesions are a common challenge in older percutaneous coronary intervention (PCI) populations. We aimed to investigate in-hospital and 1-year outcomes of octogenarian and nonagenar...
Prognostic Role of the PRECISE-DAPT Score in Acute Coronary Syndrome and Different Antithrombotic Treatment Strategies [0.03%]
PRECISE-DAPT评分在急性冠脉综合征不同抗栓治疗策略中的预后价值
Dávid Bauer,Adam Fojtík,Vojtěch Berka et al.
Dávid Bauer et al.
Introduction: The PRECISE-DAPT score is a useful tool for predicting the risk of bleeding after percutaneous coronary intervention (PCI) requiring dual antiplatelet therapy. We aimed to validate the PRECISE-DAPT score as ...
Study Design and Baseline Characteristics of the VERINA Study: Phase IV Evidence of Vericiguat for Worsening Heart Failure Management [0.03%]
VERINA研究的设计及基线特征：vericiguat治疗心力衰竭恶化的IV期证据
Jabir Abdulakutty,Atul Abhyankar,Sandeep Seth et al.
Jabir Abdulakutty et al.
Introduction: Patients with heart failure with reduced ejection fraction (HFrEF) experience higher rates of in-hospital and all-cause mortality. On the basis of the VERINA trial, vericiguat is indicated for patients who h...
Real-World Outcomes Among Patients in the United States Receiving Tafamidis for Transthyretin Amyloid Cardiomyopathy [0.03%]
美国因甲状腺素转运蛋白淀粉样心肌病接受tafamidis治疗的患者的真实世界结局
Daniel P Judge,Margarita Udall,Andrew M Rosen et al.
Daniel P Judge et al.
Introduction: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. Tafamidis demonstrated efficacy in ATTR-CM clinical trials; however, real-world disease outcomes are not thoroughly chara...
Functionally Limiting Symptoms and Inability to Independently Complete Daily Activities Increase the Burden Felt by Caregivers to Patients with ATTR-CM [0.03%]
ATTR性心肌病患者的护理负担与功能限制症状及无法独立完成日常活动的能力增加有关
Francesco Cappelli,Lucia Ponti,Martina Smorti et al.
Francesco Cappelli et al.
Introduction: The Burden of Disease survey characterized the humanistic burden of transthyretin amyloid cardiomyopathy (ATTR-CM) in 208 international patients not receiving disease-modifying therapy and their primary care...
Colchicine Among Patients with Acute Coronary Syndrome: A Meta-Analysis of Randomized Trials [0.03%]
急性冠脉综合征患者使用秋水仙碱的疗效及安全性：随机对照临床试验的Meta分析研究
Mohamed Hamed,Sheref A Mohamed,Mohamed Abdelazeem et al.
Mohamed Hamed et al.
Introduction: Prior trials evaluating the benefit of colchicine in patients with acute coronary syndrome (ACS) have yielded mixed results. Hence, we conducted a meta-analysis of randomized controlled trials (RCTs) to eval...
Impella vs. IABP in Non-emergent High-Risk PCI: Outcomes and LVEF Recovery from a Large US EHR Study [0.03%]
与IABP相比，伊姆佩拉在非紧急高危PCI中的效果及美国大规模EHR研究的心脏功能恢复效果分析
Jason R Wollmuth,Aditya S Bharadwaj,Nudrat Noor et al.
Jason R Wollmuth et al.
Introduction: High-risk percutaneous coronary intervention (HR-PCI) involves patients with complex coronary disease, adverse hemodynamics, and/or severe comorbidities who are often ineligible for surgery. Mechanical circu...
Real-World Adherence and Effectiveness of Inclisiran in Lowering LDL-C: Results from 1 Year of Follow-Up [0.03%]
inclisiran降低低密度脂蛋白胆固醇的现实世界依从性和有效性：为期一年的随访结果
Christie M Ballantyne,Timothy E Graham,Lucinda J Van Anglen et al.
Christie M Ballantyne et al.
Introduction: Atherosclerotic cardiovascular disease (ASCVD) is a global health concern. Reducing low-density lipoprotein cholesterol (LDL-C) is critical in ASCVD prevention and treatment. Inclisiran, a novel RNA therapeu...
Reverse Takotsubo Cardiomyopathy After an Adverse Reaction to Alteplase Treated with Intravenous Epinephrine [0.03%]
阿替普酶治疗不良反应所致应激性心肌病一例及静脉注射肾上腺素的治疗效果
Charles G Kinzig,Matthew R Carey,Lauren P Waldman et al.
Charles G Kinzig et al.
Takotsubo (stress) cardiomyopathy (TTC) is an uncommon acute heart failure syndrome characterized by transient hypocontractility that usually affects a circumferential segment of the myocardium along the heart's apicobasal axis and spans mu...